Wyeth’s Vaccines Pipeline Is Stacked With Blockbuster Potential
Executive Summary
Following on the multi-billion dollar success of Prevnar, Wyeth's vaccines unit is turning to a new generation of products to drive growth in 2009 and beyond
You may also be interested in...
Why Wyeth's Talking Up Vaccines
Given the near-term generic threats to over a third of its US drug revenues and two late-stage set-backs last year, Wyeth's vaccines business--basically the $3 billion-and-growing pneumococcal vaccine Prevnar--matters more than ever before. So, then, does eliminating an imminent competitive threat from GlaxoSmithKline, and a swift switch to follow-on Prevnar 13 in 2010. Indeed, vaccine chiefs at the other four big players-Sanofi-Aventis, Merck & Co. Inc., GlaxoSmithKline PLC, and Novartis AG-are likely to become more prominent, too. Vaccines may still account for only a small minority of revenues at these Big Pharma, but most saw far healthier growth in their vaccines business in 2007 than in therapeutics. That's why Sanofi, according to recent media reports, is out looking for vaccine acquisitions.
Vaccines Are A Booster To Drug Makers In Q3 – Signs Of A Strategy Paying Off
As generic threats, drug safety and poor pipeline productivity continued to weigh on Wall Street's expectations for big pharma, vaccines were one bright spot in the third quarter
Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries
Pediatric pneumococcal vaccines in development by Wyeth and GlaxoSmithKline could be the first products to benefit from a pilot program designed to create an incentive to develop vaccines that treat the diseases of the developing world